Description

Adipotide (FTPP) – Targeted Fat Loss Peptide

Overview
Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), is an experimental peptide designed to selectively reduce white adipose tissue. It works by targeting blood vessels that supply fat cells, cutting off their nutrient flow and triggering fat cell death. Unlike traditional fat-loss methods, Adipotide acts directly on fat tissue rather than affecting appetite or metabolism.

Benefits

• Promotes rapid reduction of body fat, including visceral fat
• May improve insulin sensitivity and metabolic health
• Targets fat tissue without stimulant effects
• Works independently of appetite suppression
• Supports improved body composition

Mechanism of Action
Adipotide binds to specific receptors on blood vessels that supply white fat tissue. This binding triggers apoptosis in the vessels, reducing blood flow to fat cells. The lack of nutrients causes fat cells to break down and be gradually eliminated from the body.

Dosing (Research Use Only)

• Typical dose: ~0.43 mg/kg of body weight
• Dose range: 0.1 – 0.75 mg/kg
• Frequency: Once daily
• Cycle length: 4–6 weeks
• Administration: Subcutaneous injection
• Injection sites: Abdomen, thighs, or glutes, rotating sites to reduce irritation

Expected Results

• Week 1–2: Initial reduction in waist or abdominal circumference
• Week 2–4: Noticeable fat loss and improved body composition
• Post-cycle: Maintenance depends on lifestyle and diet; some rebound may occur

Side Effects

• Common: Injection site irritation, fatigue, nausea, dehydration, electrolyte imbalance, elevated creatinine levels
• Serious: Dose-dependent kidney toxicity, potential renal damage, reduced kidney function, systemic stress from rapid fat breakdown

Warnings

• Not approved for human use
• Limited clinical data on safety and efficacy
• Effects on fat tissue are permanent
• Should not be used by individuals with kidney disease, dehydration, or electrolyte imbalance
• Not suitable during pregnancy or breastfeeding

Summary
Adipotide is an experimental peptide that offers a unique approach to fat loss by directly targeting fat tissue through vascular disruption. It has shown significant fat reduction in research studies, but safety concerns—particularly regarding kidney health—limit its use, and human clinical data are lacking.